117 related articles for article (PubMed ID: 23443308)
1. Dodging a dogma: is treating beyond progression beneficial?
Naing A; Kurzrock R
Cancer Chemother Pharmacol; 2013 May; 71(5):1385-6. PubMed ID: 23443308
[No Abstract] [Full Text] [Related]
2. Progressive thoughts about progressive disease.
Shah NP
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5229-31. PubMed ID: 17875748
[No Abstract] [Full Text] [Related]
3. Introduction to resistance to anticancer agents.
Kruh GD
Oncogene; 2003 Oct; 22(47):7262-4. PubMed ID: 14576836
[No Abstract] [Full Text] [Related]
4. Chemotherapy resistance and retreatment: a dogma revisited.
Naing A; Kurzrock R
Clin Colorectal Cancer; 2010 Apr; 9(2):E1-4. PubMed ID: 20378496
[TBL] [Abstract][Full Text] [Related]
5. p53 and response to chemotherapy and radiotherapy.
Ruley HE
Important Adv Oncol; 1996; ():37-56. PubMed ID: 8791127
[No Abstract] [Full Text] [Related]
6. [Resistance to cytostatic drugs].
Elonen E
Duodecim; 1998; 114(13):1319-28. PubMed ID: 11552258
[No Abstract] [Full Text] [Related]
7. JAMA Oncology Patient Page. The Evolution of a Cancer.
West HJ; Jin JO
JAMA Oncol; 2015 Sep; 1(6):850. PubMed ID: 26247697
[No Abstract] [Full Text] [Related]
8. Criticism of tumor response criteria raises trial design questions.
Twombly R
J Natl Cancer Inst; 2006 Feb; 98(4):232-4. PubMed ID: 16478740
[No Abstract] [Full Text] [Related]
9. [Tyrosine kinases as targets of cancer therapy: from disbelief to Lazarus responses].
Joensuu H
Duodecim; 2012; 128(21):2261-8. PubMed ID: 23210289
[TBL] [Abstract][Full Text] [Related]
10. Thymidylate synthase inhibitors.
Ismail AS; Grem JL
Cancer Chemother Biol Response Modif; 2001; 19():1-19. PubMed ID: 11686010
[No Abstract] [Full Text] [Related]
11. Achilles heels and Trojan horses against drug-resistant tumor cells.
Park K
J Control Release; 2011 Jan; 149(2):91. PubMed ID: 21167115
[No Abstract] [Full Text] [Related]
12. Combining targeted drugs to stop resistant tumors.
Kaiser J
Science; 2011 Mar; 331(6024):1542-5. PubMed ID: 21436437
[No Abstract] [Full Text] [Related]
13. Targeted therapies: the answer to individualized treatment?
Hutchinson L
Nat Clin Pract Oncol; 2007 Jun; 4(6):323. PubMed ID: 17534387
[No Abstract] [Full Text] [Related]
14. Cancer and natural selection.
Fillon M
J Natl Cancer Inst; 2012 Dec; 104(23):1773-4. PubMed ID: 23213180
[No Abstract] [Full Text] [Related]
15. Polycythemia vera evolving into a rapidly progressive Ph-negative del(5q)-positive myeloproliferative neoplasm refractory to lenalidomide.
Dasanu CA; Schwartz RA; Bauer F; Davis LK; Silver JS; Reale MA
Leuk Res; 2011 May; 35(5):e41-3. PubMed ID: 21288571
[No Abstract] [Full Text] [Related]
16. [Current status of anticancer chemotherapy. Progress in concept, methods and means].
Chauvergne J
Rev Laryngol Otol Rhinol (Bord); 1977; 98(5-6):271-89. PubMed ID: 897407
[No Abstract] [Full Text] [Related]
17. Disease progression in some cancers may be due to low blood levels of targeted therapies.
Tuma RS
J Natl Cancer Inst; 2008 Jul; 100(13):912-3. PubMed ID: 18577740
[No Abstract] [Full Text] [Related]
18. Anticancer drugs.
Reese DM
Nature; 1995 Dec; 378(6557):532. PubMed ID: 8524372
[No Abstract] [Full Text] [Related]
19. Farnesyl transferase inhibitors.
Li T; Sparano JA
Cancer Invest; 2008 Aug; 26(7):653-61. PubMed ID: 18665473
[No Abstract] [Full Text] [Related]
20. Targeted therapy: overcoming drug resistance with clinical cancer genome.
Ziogas DE; Katsios CS; Tzaphlidou M; Roukos DH
Expert Rev Anticancer Ther; 2012 Jul; 12(7):861-4. PubMed ID: 22845399
[No Abstract] [Full Text] [Related]
[Next] [New Search]
